TheraSphere™ Press Releases

11 Jun 2018

ELEVATE study aims to improve selection criteria and outcomes for patients wi...

BTG plc (LSE: BTG), the global healthcare company, today announces the start of ELEVATE: A randomizEd ControlLed Study of PnEumRx™ Endobronchial Coil System (Coils) Versus Standard of Care Medical MAnagement in the Treatment of Subjects with Severe Emphysema.

21 Feb 2018

First Patient in Latin America Receives TheraSphere® Radioembo...

February 28, 2018: BTG plc (LSE: BTG), a global specialist healthcare company, announced the first patient in Latin America in Mexico was treated with TheraSphere® – a treatment for hepatic neoplasia that delivers powerful radiation to tumour cells and minimizes the exposure to healthy tissue.

11 Dec 2017

Institutional Decision to Adopt Y90 TARE with TheraSphere® as first-line ...

Based on experience with 1000 patients over 15 years, the largest single-centre, prospective centre cohort of patients with HCC treated with Y90 glass microspheres

5 Oct 2017

BTG plc acquires Roxwood Medical

London, UK, 5 October 2017: BTG plc (LSE: BTG), the global specialist healthcare company, today announces it has acquired Roxwood Medical (“Roxwood”), an innovative provider of advanced cardiovascular specialty catheters used in the treatment of patients with severe coronary and peripheral artery disease.

27 Sep 2017

Mirada Medical signs three-year software development agreement with BTG

Mirada Medical Ltd, a global medical imaging software company, has signed a three-year master service agreement with BTG plc (LSE: BTG), a global specialist healthcare company. The agreement covers multiple software development projects to support BTG’s portfolio of interventional medicine products.

21 Aug 2017

BTG and SIO expand Immuno-Oncology / Interventional Oncology grant programme

BTG plc (LSE: BTG), a global specialist healthcare company, and the Society of Interventional Oncology (SIO), an international organisation working to nurture and support interventional oncology worldwide, have expanded their commitment to the Immuno-Oncology / Interventional Oncology research grant programme, by announcing a second round of funding available to investigators.

10 Jun 2017

New study shows IO Loop™ improves patient follow-up, engagement and sat...

Study shows patients treated with TheraSphere® maintain quality of life throughout 90 day post-treatment period

19 May 2017

BTG and HealthLoop collaborate on IO Loop™, an exclusive service to con...

Data from a pilot study using IO Loop™ with TheraSphere® (a 90Y transarterial radioembolisation therapy) will be presented at the World Conference on Interventional Oncology

15 Feb 2017

BTG and Society of Interventional Oncology to explore role of minimally invas...

BTG plc (LSE: BTG), the global specialist healthcare company, today announced a collaboration with the Society of Interventional Oncology (SIO), a global organization working to nurture and support interventional oncology worldwide, to explore the role of interventional oncology alongside immuno-oncology

5 Dec 2016

PneumRx® Coils included in new global clinical guidelines and ...

BTG plc (LSE: BTG), the global specialist healthcare company, today announces the inclusion of treatment with PneumRx® Coils in guidelines for the management of chronic obstructive pulmonary disease (COPD) published by the Global Initiative for Chronic Obstructive Lung Disease (GOLD).